UNCY · Unicycive Therapeutics, Inc.

Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $4.90, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.

Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.

Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

2,500 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter.

22,500 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter.

2,500 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

81,250 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter.

The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.

Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $0.49, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.

Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.

Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $0.49, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.

Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

20,438 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter.

10,064 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter.

20,438 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

58,217 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter.

115,813 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

329,896 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

57,030 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

115,813 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

63,079 options vest on June 26, 2024, 63,079 options vest on June 26, 2025 and 63,078 vest on June 26, 2026.

37,382 options vest on June 26, 2024, 37,382 options vest on June 26, 2025 and 37,383 vest on June 26, 2026.

1,171,194 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter.

338,750 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

142,582 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter.

338,750 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 41,845 shares of common stock, (2) a Tranche A Warrant to purchase 31,700 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 28,818 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 46,110 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb.

On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment.

On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date.

The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones.

Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date.

Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb.

On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date.

The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones.

Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date.

Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion.